Quote | Biomea Fusion Inc. (NASDAQ:BMEA)
Last: | $13.195 |
---|---|
Change Percent: | 6.67% |
Open: | $12.59 |
Close: | $12.37 |
High: | $13.29 |
Low: | $12.515 |
Volume: | 566,544 |
Last Trade Date Time: | 05/15/2024 03:00:00 am |
News | Biomea Fusion Inc. (NASDAQ:BMEA)
2024-05-09 14:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-03 01:50:22 ET More on Biomea Fusion Why Biomea Fusion Is A 'Hold': A Bet On Diabetes And Oncology Research Biomea Fusion drops as JPMorgan downgrades on data for lead asset Seeking Alpha’s Quant Rating on Biomea Fusion Historical earnings data...
Message Board Posts | Biomea Fusion Inc. (NASDAQ:BMEA)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $BMEA morning dip S30.4 BO32.5 does it push HH | znewcar1 | investorshangout | 03/30/2023 2:16:47 PM |
znewcar1: $BMEA 99% v18,2M c30.71 f29,396M H31.54 First Post! Big day gap chop N go it 29.47 then di | znewcar1 | investorshangout | 03/28/2023 8:31:17 PM |
$BMEA: Whether or not my 'BANK' is collapsing | Invest-in-America | investorshub | 03/28/2023 8:31:11 PM |
$BMEA: And I'll bet that YOU, Boss, grabbed | Invest-in-America | investorshub | 03/28/2023 5:19:46 PM |
https://investors.biomeafusion.com/news-releases/news-release-details/biomea-fus | TheFinalCD | investorshub | 03/28/2023 5:13:06 PM |
News, Short Squeeze, Breakout and More Instantly...
Biomea Fusion Inc. Company Name:
BMEA Stock Symbol:
NASDAQ Market:
2024-05-09 14:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Reported positive data from the escalation portion of Phase 1/2 study (COVALENT-111) in type 2 diabetes patients, displaying durable improved glycemic control while off therapy for 22 weeks, supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healt...
REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically d...